Everything I say is in my opinion, do your own DD and make your decision wisely! Don't spend more then you can afford to lose, OTC's are Cruel at Best
Followers | 1066 |
Posts | 135,767 |
Boards Moderated | 0 |
Alias Born | 08/25/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$HMNU is bouncing slowly. Over $35,000,000 in assets with $2,000,000 cash and a share structure under a billion. Should be trading over $0.03+ and it will.
HMNU .0017 Last call before the run...
HMNU .0017 Last call before the run...
$HMNU .0017 Same SS, traded at $0.055+ $35,000,000 Assets.
$HMNU .0017 Same SS, traded at $0.055+ $35,000,000 Assets.
$HMNU .0016 Huge Partnership and Contract Human Unitec International Inc. is pleased to announce the conclusion of a contractual agreement with the CGT Group, a joint venture between Neutel Srl and Engineer
https://www.neutel.com/
$HMNU .0016 Huge Partnership and Contract Human Unitec International Inc. is pleased to announce the conclusion of a contractual agreement with the CGT Group, a joint venture between Neutel Srl and Engineer
https://www.neutel.com/
HMNU tic toc $35m asset vs $1m Cap
HMNU tic toc $35m asset vs $1m Cap
$HMNU bids growing, news coming, $35m assets, $2m cash
$HMNU bids growing, news coming, $35m assets, $2m cash.
$HMNU keep it on high alert, breakout imminent.
$HMNU keep it on high alert, breakout imminent.
$HMNU .0016 bouncing off bottom, $35,000,000+ Assets with over $2,000,000 cash
$HMNU .0016 bouncing off bottom, $35,000,000+ Assets with over $2,000,000 cash
$BNOW .0053 2.3m Share Slap!!
$BNOW .0053 2.3m Share Slap!!
Who throws up 3.8m, seriously...
$BNOW .004 $10,000,000 News >>
HUGE NEWS
BOON now has the capability to produce DiOx+ and BioDox at a projected initial annual capacity of twenty-five thousand cases per year with a potential estimated wholesale value of over $10,000,000.
https://www.otcmarkets.com/stock/BNOW/news/BOON-Significantly-Expands-Production-Capabilities?id=333507
$BNOW .004 $10,000,000 News >>
HUGE NEWS
BOON now has the capability to produce DiOx+ and BioDox at a projected initial annual capacity of twenty-five thousand cases per year with a potential estimated wholesale value of over $10,000,000.
https://www.otcmarkets.com/stock/BNOW/news/BOON-Significantly-Expands-Production-Capabilities?id=333507
$BNOW .0041 Solid News 300m O/S >> Boon Industries Retains Wallrich Creative Communications for Branding and MarketingPress Release | 01/07/2022
SACRAMENTO, CA, Jan. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Boon Industries, Inc. (OTC PINK: BNOW) (“Boon” or the “Company”), an innovative bioscience company delivering solutions that benefit people and the planet, is pleased to announce that the Company has retained renowned agency Wallrich Creative Communications as the Company prepares to launch its full suite of BioDox products in the first quarter of 2022.
Wallrich will immediately begin work on Boon’s logo, branding, and messaging needs, creating the essential marketing deliverables for the Company’s new go-to-market initiative.
Wallrich Creative Communications is a full-service marketing communications firm established in Sacramento, CA in 1990. With comprehensive capability to support branding, marketing, advertising, and interactive initiatives, the Wallrich team integrates strategy, content, visual design, and technical development at an exceptional level of proven expertise for a seamless service approach. Wallrich has deep experience serving clients in healthcare, bioscience, agriculture, energy, education, nonprofit, and professional service sectors, with regional and national examples that include the Sacramento Municipal Utility District, The Morning Star Company, and CommonSpirit Health.
“We are ecstatic to have engaged a prestigious agency with a portfolio of successes doing exactly what we want to do and with whom we share a common ethos of sustainable and effective product offerings,” stated Justin Gonzalez, Chairman, Boon Industries. “Additionally, we are working directly with the firm’s founder and creative force, Lila Wallrich, tapping into her amazing talents and experience at the design table and in the marketplace.”
“Our team was intrigued when we learned about Boon’s mission and products, which align perfectly with our interest in solutions that improve people’s lives while protecting the environment. We’re honored by this opportunity to help articulate and promote Boon’s brand in the marketplace,” Lila Wallrich, Creative Director and CEO.
About Boon Industries
Boon Industries, Inc. (OTC: BNOW) is an innovative bioscience company delivering solutions that benefit people and the planet. At the core of Boon’s product offering is DiOx+™, a chlorine dioxide disinfectant sterilizer. Chlorine dioxide has been approved by OSHA, FDA, EPA, and DOT. DiOx+ kills harmful pathogens without dangerous toxic exposure to the user or the environment. The proprietary chemical formulas and processes behind DiOx+ make it ideal for sterilization of mission critical, high value medical equipment and disinfecting air and surfaces in laboratory and hospital environments. DiOx+ helps protect agricultural crops from disease, is used in water treatment plants, and helps reduce operational costs in warehousing, distribution centers and ecommerce support facilities. The introduction of DiOx+ to the U.S. market follows 12 years of chlorine dioxide usage in global markets driven by Boon’s CEO Justin Gonzalez. DiOx+ delivers on Boon’s promise to provide the most effective, affordable solutions without sacrificing health and safety
$BNOW .0041 Solid News 300m O/S >> Boon Industries Retains Wallrich Creative Communications for Branding and MarketingPress Release | 01/07/2022
SACRAMENTO, CA, Jan. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Boon Industries, Inc. (OTC PINK: BNOW) (“Boon” or the “Company”), an innovative bioscience company delivering solutions that benefit people and the planet, is pleased to announce that the Company has retained renowned agency Wallrich Creative Communications as the Company prepares to launch its full suite of BioDox products in the first quarter of 2022.
Wallrich will immediately begin work on Boon’s logo, branding, and messaging needs, creating the essential marketing deliverables for the Company’s new go-to-market initiative.
Wallrich Creative Communications is a full-service marketing communications firm established in Sacramento, CA in 1990. With comprehensive capability to support branding, marketing, advertising, and interactive initiatives, the Wallrich team integrates strategy, content, visual design, and technical development at an exceptional level of proven expertise for a seamless service approach. Wallrich has deep experience serving clients in healthcare, bioscience, agriculture, energy, education, nonprofit, and professional service sectors, with regional and national examples that include the Sacramento Municipal Utility District, The Morning Star Company, and CommonSpirit Health.
“We are ecstatic to have engaged a prestigious agency with a portfolio of successes doing exactly what we want to do and with whom we share a common ethos of sustainable and effective product offerings,” stated Justin Gonzalez, Chairman, Boon Industries. “Additionally, we are working directly with the firm’s founder and creative force, Lila Wallrich, tapping into her amazing talents and experience at the design table and in the marketplace.”
“Our team was intrigued when we learned about Boon’s mission and products, which align perfectly with our interest in solutions that improve people’s lives while protecting the environment. We’re honored by this opportunity to help articulate and promote Boon’s brand in the marketplace,” Lila Wallrich, Creative Director and CEO.
About Boon Industries
Boon Industries, Inc. (OTC: BNOW) is an innovative bioscience company delivering solutions that benefit people and the planet. At the core of Boon’s product offering is DiOx+™, a chlorine dioxide disinfectant sterilizer. Chlorine dioxide has been approved by OSHA, FDA, EPA, and DOT. DiOx+ kills harmful pathogens without dangerous toxic exposure to the user or the environment. The proprietary chemical formulas and processes behind DiOx+ make it ideal for sterilization of mission critical, high value medical equipment and disinfecting air and surfaces in laboratory and hospital environments. DiOx+ helps protect agricultural crops from disease, is used in water treatment plants, and helps reduce operational costs in warehousing, distribution centers and ecommerce support facilities. The introduction of DiOx+ to the U.S. market follows 12 years of chlorine dioxide usage in global markets driven by Boon’s CEO Justin Gonzalez. DiOx+ delivers on Boon’s promise to provide the most effective, affordable solutions without sacrificing health and safety
$HMNU .0102 BIG TWEET >> $HMNU
Happy New Year
Our new CEO will be providing updates next week. Thank you
$HMNU
— @HMNU (@HMNU_1) January 6, 2022
Happy New Year
Our new CEO will be providing updates next week. Thank you
$HMNU .0102 BIG TWEET >> $HMNU
Happy New Year
Our new CEO will be providing updates next week. Thank you
$HMNU
— @HMNU (@HMNU_1) January 6, 2022
Happy New Year
Our new CEO will be providing updates next week. Thank you
$SPSO .0225 Up
$SPSO .0225 Up
$SPSO .02 Pink Current, Next $SIRC .05 to $3.00+
$SPSO .02 Pink Current, Next $SIRC .05 to $3.00+
$PGLO .009 up Huge Acquisition Flywheel and Radiologics Join Forces to Create a Truly Unique Global Network for Biomedical Research and Collaboration
Flywheel is the revolutionary research data management platform powering healthcare innovation by accelerating collaboration, enabling machine learning, and streamlining the massive task of data aggregation, curation and management. (Graphic: Flywheel)
September 15, 2021 07:00 AM Eastern Daylight Time
MINNEAPOLIS--(BUSINESS WIRE)--Flywheel, the leading biomedical research data management platform, today announces the acquisition of St. Louis-based Radiologics. The two organizations’ combined capabilities in imaging research data management and analytics provide the medical research community unrivaled end-to-end research workflow solutions—from open source to global enterprise. Together, the two companies, now operating as Flywheel, offer the only biomedical research platform that can connect any organization or data set across academia, life sciences, clinical, and medical AI.
Exciting biomedical research data industry news: @Flywheel_io & Radiologics joined forces! Together, they offer the only biomedical research platform that can connect any organization or data set across academia, life sciences, clinical, and medical AI.
Tweet this
“Big data plays a pivotal role in healthcare innovation. And realizing the full potential of innovation requires better data management,” said Jim Olson, Flywheel CEO. “The combined Flywheel and Radiologics capabilities uniquely enable increased collaboration among the brightest scientific and medical minds and the best data sets in the industry, making it possible for the smallest labs to collaborate with the largest academic medical centers and commercial enterprises. Our goal is to power accelerated R&D in oncology, radiology and other therapeutic areas where innovation is paramount and increasingly data-driven.”
Flywheel will now offer:
Cross-platform data and algorithm interoperability.
An accelerated roadmap of new features and tools.
An expanded network with more opportunities for research collaboration.
Secure and compliant data discovery across a global network of opted-in innovators.
Cloud-scalable and on-premise computational workflows for research and clinical applications.
“Together, we’re going to help speed the development of clinical trials, get to discovery faster, and reduce wasted time and resources along the way. We understood the tremendous opportunity to bring together Flywheel’s and Radiologics’ expertise for the advancement of medical research,” said Dan Marcus, PhD, Radiologics CEO, who will take on the role of Chief Scientific Officer at Flywheel. “I’m thrilled that our combined company will continue to serve the research community through open source and enterprise informatics solutions.”
“I am incredibly excited about the news that Flywheel and Radiologics are joining forces. This opens up a lot of opportunities for our MRI Unit and Department of Psychiatry to more seamlessly collaborate with other departments at Columbia, as well as outside the institution,” said Rachel Marsh, PhD, Irving Philips Professor of Medical Psychology at Columbia University Irving Medical Center, and Director of the MRI Research Program at the New York State Psychiatric Institute. “I look forward to being able to access the combined expertise of both Flywheel and Radiologics and to being part of their extensive network of researchers who can now more easily work together on a common platform to drive faster discovery.”
In addition to Flywheel’s cloud-based research data platform, the company will offer original Radiologics products and services—a full range of imaging informatics services around the XNAT platform, including consulting, technical support, software development, custom image processing pipelines, and staffing solutions.
“At the end of the day, we’re here to take care of the data, so researchers can focus on what matters most—science, innovation and creating life-changing therapies,” added Olson.
About Flywheel
Flywheel is the revolutionary research data management platform powering healthcare innovation by accelerating collaboration, enabling machine learning, and streamlining the massive task of data aggregation, curation and management. By leveraging cloud scalability and automating research workflows, Flywheel helps organizations scale research data and analysis, improve scientific collaboration and accelerate discoveries. Flywheel offers comprehensive solutions for life sciences, pharmaceutical, biotech, academic, and clinical research. Flywheel is headquartered in Minneapolis and has offices in the Bay Area, St. Louis, and Budapest. For more information, visit www.flywheel.io or follow us on LinkedIn and Twitter.
?
Contacts
Media contact:
Amanda Rueb
Inprela Communications
amanda@inprela.com
?
FLYWHEEL
Terms of Use
© 2022 Business Wire
$PGLO .009 up Huge Acquisition Flywheel and Radiologics Join Forces to Create a Truly Unique Global Network for Biomedical Research and Collaboration
Flywheel is the revolutionary research data management platform powering healthcare innovation by accelerating collaboration, enabling machine learning, and streamlining the massive task of data aggregation, curation and management. (Graphic: Flywheel)
September 15, 2021 07:00 AM Eastern Daylight Time
MINNEAPOLIS--(BUSINESS WIRE)--Flywheel, the leading biomedical research data management platform, today announces the acquisition of St. Louis-based Radiologics. The two organizations’ combined capabilities in imaging research data management and analytics provide the medical research community unrivaled end-to-end research workflow solutions—from open source to global enterprise. Together, the two companies, now operating as Flywheel, offer the only biomedical research platform that can connect any organization or data set across academia, life sciences, clinical, and medical AI.
Exciting biomedical research data industry news: @Flywheel_io & Radiologics joined forces! Together, they offer the only biomedical research platform that can connect any organization or data set across academia, life sciences, clinical, and medical AI.
Tweet this
“Big data plays a pivotal role in healthcare innovation. And realizing the full potential of innovation requires better data management,” said Jim Olson, Flywheel CEO. “The combined Flywheel and Radiologics capabilities uniquely enable increased collaboration among the brightest scientific and medical minds and the best data sets in the industry, making it possible for the smallest labs to collaborate with the largest academic medical centers and commercial enterprises. Our goal is to power accelerated R&D in oncology, radiology and other therapeutic areas where innovation is paramount and increasingly data-driven.”
Flywheel will now offer:
Cross-platform data and algorithm interoperability.
An accelerated roadmap of new features and tools.
An expanded network with more opportunities for research collaboration.
Secure and compliant data discovery across a global network of opted-in innovators.
Cloud-scalable and on-premise computational workflows for research and clinical applications.
“Together, we’re going to help speed the development of clinical trials, get to discovery faster, and reduce wasted time and resources along the way. We understood the tremendous opportunity to bring together Flywheel’s and Radiologics’ expertise for the advancement of medical research,” said Dan Marcus, PhD, Radiologics CEO, who will take on the role of Chief Scientific Officer at Flywheel. “I’m thrilled that our combined company will continue to serve the research community through open source and enterprise informatics solutions.”
“I am incredibly excited about the news that Flywheel and Radiologics are joining forces. This opens up a lot of opportunities for our MRI Unit and Department of Psychiatry to more seamlessly collaborate with other departments at Columbia, as well as outside the institution,” said Rachel Marsh, PhD, Irving Philips Professor of Medical Psychology at Columbia University Irving Medical Center, and Director of the MRI Research Program at the New York State Psychiatric Institute. “I look forward to being able to access the combined expertise of both Flywheel and Radiologics and to being part of their extensive network of researchers who can now more easily work together on a common platform to drive faster discovery.”
In addition to Flywheel’s cloud-based research data platform, the company will offer original Radiologics products and services—a full range of imaging informatics services around the XNAT platform, including consulting, technical support, software development, custom image processing pipelines, and staffing solutions.
“At the end of the day, we’re here to take care of the data, so researchers can focus on what matters most—science, innovation and creating life-changing therapies,” added Olson.
About Flywheel
Flywheel is the revolutionary research data management platform powering healthcare innovation by accelerating collaboration, enabling machine learning, and streamlining the massive task of data aggregation, curation and management. By leveraging cloud scalability and automating research workflows, Flywheel helps organizations scale research data and analysis, improve scientific collaboration and accelerate discoveries. Flywheel offers comprehensive solutions for life sciences, pharmaceutical, biotech, academic, and clinical research. Flywheel is headquartered in Minneapolis and has offices in the Bay Area, St. Louis, and Budapest. For more information, visit www.flywheel.io or follow us on LinkedIn and Twitter.
?
Contacts
Media contact:
Amanda Rueb
Inprela Communications
amanda@inprela.com
?
FLYWHEEL
Terms of Use
© 2022 Business Wire
$PGLO .008 Last 1, was $0.178
$PGLO .008 Last 1, was $0.178
$PGLO .008 +33% next $PRMK Merger Coming 40m Float
$PGLO .008 +33% next $PRMK Merger Coming 40m Float
$CBDD .0048 $21M 9 months...CBD of Denver Files Q3 Financial Statements and Reports Revenue Up 300% Year-Over-Year in the First Nine Months of 2021Press Release | 12/02/2021
Denver, Colorado--(Newsfile Corp. - December 2, 2021) - CBD of Denver, Inc. (OTC Pink: CBDD), a cultivator and distributor of CBD and cannabis flower and a producer of a full line of CBD oil and unique products sold in Switzerland and throughout Europe, filed its third quarter financial statements on OTCMarkets.com for the period ended September 30, 2021.
CBD of Denver generated $20.9 million revenue in the first nine months of 2021, up 300% year-over-year compared to $6.0 million in the first nine months of 2020. Gross profit in the first nine months of 2021 was $1.1 million, compared to gross profit of $0.5 million in the same period of 2020.
Q3 Business Highlights:
Customer base increased to over 800 customers across Europe, including more than 450 recurring customers, as of the end of the third quarter of 2021
Delivering products into 12 countries across Europe as of the end of the third quarter of 2021
"We are very pleased to report strong year-over-year revenue growth in the first nine months of 2021, and importantly, year-to-date, we have already surpassed our 2021 revenue guidance of $22 million (USD)," commented Marcel Gamma, CEO. "The Company remains focused on continued growth while simultaneously moving forward on the completion of its GAAP audit required to become a fully reporting issuer with the SEC, which will enable the Company to move beyond the OTC Pink Market where it can provide investors with improved transparency and increased liquidity."
A key driver of the Company's year-to-date performance has been its Rockflowr brand. CBD of Denver has successfully completed a rebranding Rockflowr, GmbH to Rockflowr Exchange and Rockflowr Production as it works to become the top European player in the space.
Follow CBDD on Instagram: @SwissCBDTrading @Rockflowr @CBDofDenver_Inc @SwissGreenGrow @RockflowrRetail
CBD of Denver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG are now also on LinkedIn.
$CBDD .0048 $21M 9 months...CBD of Denver Files Q3 Financial Statements and Reports Revenue Up 300% Year-Over-Year in the First Nine Months of 2021Press Release | 12/02/2021
Denver, Colorado--(Newsfile Corp. - December 2, 2021) - CBD of Denver, Inc. (OTC Pink: CBDD), a cultivator and distributor of CBD and cannabis flower and a producer of a full line of CBD oil and unique products sold in Switzerland and throughout Europe, filed its third quarter financial statements on OTCMarkets.com for the period ended September 30, 2021.
CBD of Denver generated $20.9 million revenue in the first nine months of 2021, up 300% year-over-year compared to $6.0 million in the first nine months of 2020. Gross profit in the first nine months of 2021 was $1.1 million, compared to gross profit of $0.5 million in the same period of 2020.
Q3 Business Highlights:
Customer base increased to over 800 customers across Europe, including more than 450 recurring customers, as of the end of the third quarter of 2021
Delivering products into 12 countries across Europe as of the end of the third quarter of 2021
"We are very pleased to report strong year-over-year revenue growth in the first nine months of 2021, and importantly, year-to-date, we have already surpassed our 2021 revenue guidance of $22 million (USD)," commented Marcel Gamma, CEO. "The Company remains focused on continued growth while simultaneously moving forward on the completion of its GAAP audit required to become a fully reporting issuer with the SEC, which will enable the Company to move beyond the OTC Pink Market where it can provide investors with improved transparency and increased liquidity."
A key driver of the Company's year-to-date performance has been its Rockflowr brand. CBD of Denver has successfully completed a rebranding Rockflowr, GmbH to Rockflowr Exchange and Rockflowr Production as it works to become the top European player in the space.
Follow CBDD on Instagram: @SwissCBDTrading @Rockflowr @CBDofDenver_Inc @SwissGreenGrow @RockflowrRetail
CBD of Denver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG are now also on LinkedIn.
$CBDD .0047 AUDIT ANY DAY >> CBD of Denver Nears Completion of GAAP AuditPress Release | 12/06/2021
Denver, Colorado--(Newsfile Corp. - December 6, 2021) - CBD of Denver, Inc. (OTC Pink: CBDD), a cultivator and distributor of CBD and cannabis flower and a producer of a full line of CBD oil and unique products sold in Switzerland and throughout Europe, is pleased to report it has received what it believes will be the last request for information needed to complete its GAAP audit, which is being conducted by Fruci and Associates ("Fruci").
The Company contracted Fruci in February 2021. In preparation for its US GAAP audit, the Company also hired a Swiss auditing firm in January 2021 to compile the required information needed to complete the audit. Fruci had a substantial backlog when retained and only began working on CBD of Denver's over the summer. With diverse operations across the EU, the audit of the Company is more complex than for a traditional US company, requiring much longer to complete.
"We have been told by Fruci that barring any additional information needed, the audit should be done soon," commented Marcel Gamma, CEO. "It has been very frustrating watching market makers continuously hamper the movement of our stock when operating results and significant milestones have been met by the team. While our initial audit timeline expectations were overly optimistic, we are continuing to move forward with our plans to become fully reporting and move to a senior exchange as soon as we have the completed audit."
Follow CBDD on Instagram: @SwissCBDTrading @Rockflowr @CBDofDenver_Inc @SwissGreenGrow @RockflowrRetail
CBD of Denver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG are now also on LinkedIn.
About CBD of Denver, Inc.
CBD of Denver, Inc. (OTC Pink: CBDD) a full-line Cultivator, Distributor of CBD and Cannabis flower and a producer of a full line of CBD oil and unique products sold in Switzerland and throughout Europe. CBD of Denver, Inc. is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders and is driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis. Through our Rockflowr brands we have built a very strong European customer base by focusing on top quality products and meaningful customer relationships.
$CBDD .0047 AUDIT ANY DAY >> CBD of Denver Nears Completion of GAAP AuditPress Release | 12/06/2021
Denver, Colorado--(Newsfile Corp. - December 6, 2021) - CBD of Denver, Inc. (OTC Pink: CBDD), a cultivator and distributor of CBD and cannabis flower and a producer of a full line of CBD oil and unique products sold in Switzerland and throughout Europe, is pleased to report it has received what it believes will be the last request for information needed to complete its GAAP audit, which is being conducted by Fruci and Associates ("Fruci").
The Company contracted Fruci in February 2021. In preparation for its US GAAP audit, the Company also hired a Swiss auditing firm in January 2021 to compile the required information needed to complete the audit. Fruci had a substantial backlog when retained and only began working on CBD of Denver's over the summer. With diverse operations across the EU, the audit of the Company is more complex than for a traditional US company, requiring much longer to complete.
"We have been told by Fruci that barring any additional information needed, the audit should be done soon," commented Marcel Gamma, CEO. "It has been very frustrating watching market makers continuously hamper the movement of our stock when operating results and significant milestones have been met by the team. While our initial audit timeline expectations were overly optimistic, we are continuing to move forward with our plans to become fully reporting and move to a senior exchange as soon as we have the completed audit."
Follow CBDD on Instagram: @SwissCBDTrading @Rockflowr @CBDofDenver_Inc @SwissGreenGrow @RockflowrRetail
CBD of Denver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG are now also on LinkedIn.
About CBD of Denver, Inc.
CBD of Denver, Inc. (OTC Pink: CBDD) a full-line Cultivator, Distributor of CBD and Cannabis flower and a producer of a full line of CBD oil and unique products sold in Switzerland and throughout Europe. CBD of Denver, Inc. is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders and is driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis. Through our Rockflowr brands we have built a very strong European customer base by focusing on top quality products and meaningful customer relationships.
$CBDD .0052 Audited Financials ANY DAY. Almost $30,000,000 in Revenue
$CBDD .0052 Audited Financials ANY DAY. Almost $30,000,000 in Revenue